p53 directly activates cystatin D/CST5 to mediate mesenchymalepithelial transition: A possible link to tumor suppression by vitamin D3

Oncotarget

Volumn 6, Issue 18, 2015, Pages 15842-15856

  Hünten, Sabine ^a   Hermeking, Heiko ^a,b  

^a UNIVERSITY OF MUNICH   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

CST5; Mesenchymal epithelial transition; p53; SNAIL; Vitamin D3

Indexed keywords

CALCITRIOL; COLECALCIFEROL; CYSTATIN; CYSTATIN D; MESSENGER RNA; NUTLIN 3; PROTEIN P53; TRANSCRIPTION FACTOR SNAIL; UNCLASSIFIED DRUG; CALCITRIOL RECEPTOR; CST5 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ARTICLE; BINDING SITE; CANCER INHIBITION; CELL CULTURE; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; CST5 GENE; EPITHELIAL MESENCHYMAL TRANSITION; GENE; GENE EXPRESSION; GENE REPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; P53 GENE; PROMOTER REGION; PROTEIN BINDING; PROTEIN INTERACTION; REGULATORY MECHANISM; UPREGULATION; BIOSYNTHESIS; DNA DAMAGE; DRUG EFFECTS; GENETICS; HCT 116 CELL LINE; HEK293 CELL LINE; METABOLISM; TUMOR CELL LINE;

CELL LINE, TUMOR; CHOLECALCIFEROL; CYSTATINS; DNA DAMAGE; EPITHELIAL-MESENCHYMAL TRANSITION; HCT116 CELLS; HEK293 CELLS; HUMANS; RECEPTORS, CALCITRIOL; SNAIL FAMILY TRANSCRIPTION FACTORS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84937821840     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4683     Document Type: Article

References (73)

1. Feldman D, Krishnan AV, Swami S, Giovannucci E and Feldman BJ. The role of vitamin D in reducing cancer risk and progression. Nature reviews cancer. 2014; 14:342-357.
2. Krishnan AV and Feldman D. Mechanisms of the anticancer and anti-inflammatory actions of vitamin D. Annual review of pharmacology and toxicology. 2011; 51:311-336.
3. Deeb KK, Trump DL and Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nature reviews cancer. 2007; 7:684-700.
4. Lamprecht SA and Lipkin M. Chemoprevention of colon cancer by calcium, vitamin D and folate: molecular mechanisms. Nature reviews cancer. 2003; 3:601-614.
5. Pereira F, Larriba MJ and Munoz A. Vitamin D and colon cancer. Endocrine-related cancer. 2012; 19:R51-71.
6. Hummel DM, Thiem U, Hobaus J, Mesteri I, Gober L, Stremnitzer C, Graca J, Obermayer-Pietsch B and Kallay E. Prevention of preneoplastic lesions by dietary vitamin D in a mouse model of colorectal carcinogenesis. The Journal of steroid biochemistry and molecular biology. 2013; 136:284-288.
7. Kovalenko PL, Zhang Z, Yu JG, Li Y, Clinton SK and Fleet JC. Dietary vitamin D and vitamin D receptor level modulate epithelial cell proliferation and apoptosis in the prostate. Cancer prevention research. 2011; 4:1617-1625.
8. Newmark HL, Yang K, Kurihara N, Fan K, Augenlicht LH and Lipkin M. Western-style diet-induced colonic tumors and their modulation by calcium and vitamin D in C57Bl/6 mice: a preclinical model for human sporadic colon cancer. Carcinogenesis. 2009; 30:88-92.
9. Ray R, Banks M, Abuzahra H, Eddy VJ, Persons KS, Lucia MS, Lambert JR and Holick MF. Effect of dietary vitamin D and calcium on the growth of androgen-insensitive human prostate tumor in a murine model. Anticancer research. 2012; 32:727-731.
10. Swami S, Krishnan AV, Wang JY, Jensen K, Horst R, Albertelli MA and Feldman D. Dietary vitamin D(3) and 1,25-dihydroxyvitamin D(3) (calcitriol) exhibit equivalent anticancer activity in mouse xenograft models of breast and prostate cancer. Endocrinology. 2012; 153:2576-2587.
11. Zinser GM, Sundberg JP and Welsh J. Vitamin D(3) receptor ablation sensitizes skin to chemically induced tumorigenesis. Carcinogenesis. 2002; 23:2103-2109.
12. Chung M, Lee J, Terasawa T, Lau J and Trikalinos TA. Vitamin D with or without calcium supplementation for prevention of cancer and fractures: an updated metaanalysis for the U.S. Preventive Services Task Force. Annals of internal medicine. 2011; 155:827-838.
13. Fedirko V, Riboli E, Tjonneland A, Ferrari P, Olsen A, Bueno-de-Mesquita HB, van Duijnhoven FJ, Norat T, Jansen EH, Dahm CC, Overvad K, Boutron-Ruault MC, Clavel-Chapelon F, Racine A, Lukanova A, Teucher B, et al. Prediagnostic 25-hydroxyvitamin D, VDR and CASR polymorphisms, and survival in patients with colorectal cancer in western European ppulations. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2012; 21:582-593.
14. Lee JE, Li H, Chan AT, Hollis BW, Lee IM, Stampfer MJ, Wu K, Giovannucci E and Ma J. Circulating levels of vitamin D and colon and rectal cancer: the Physicians' Health Study and a meta-analysis of prospective studies. Cancer prevention research. 2011; 4:735-743.
15. Yin L, Ordonez-Mena JM, Chen T, Schottker B, Arndt V and Brenner H. Circulating 25-hydroxyvitamin D serum concentration and total cancer incidence and mortality: a systematic review and meta-analysis. Preventive medicine. 2013; 57:753-764.
16. Bjelakovic G, Gluud LL, Nikolova D, Whitfield K, Krstic G, Wetterslev J and Gluud C. Vitamin D supplementation for prevention of cancer in adults. The Cochrane database of systematic reviews. 2014; 6:CD007469.
17. Bjelakovic G, Gluud LL, Nikolova D, Whitfield K, Wetterslev J, Simonetti RG, Bjelakovic M and Gluud C. Vitamin D supplementation for prevention of mortality in adults. The Cochrane database of systematic reviews. 2014; 1:CD007470.
18. Maalmi H, Ordonez-Mena JM, Schottker B and Brenner H. Serum 25-hydroxyvitamin D levels and survival in colorectal and breast cancer patients: systematic review and meta-analysis of prospective cohort studies. European journal of cancer. 2014; 50:1510-1521.
19. Mohr SB, Gorham ED, Kim J, Hofflich H and Garland CF. Meta-analysis of vitamin D sufficiency for improving survival of patients with breast cancer. Anticancer research. 2014; 34:1163-1166.
20. Wei MY, Garland CF, Gorham ED, Mohr SB and Giovannucci E. Vitamin D and prevention of colorectal adenoma: a meta-analysis. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2008; 17:2958-2969.
21. Kupferschmidt K. Uncertain verdict as vitamin D goes on trial. Science. 2012; 337:1476-1478.
22. Holick MF. Vitamin D: A millenium perspective. Journal of cellular biochemistry. 2003; 88:296-307.
23. Jones G, Prosser DE and Kaufmann M. Cytochrome P450-mediated metabolism of vitamin D. Journal of lipid research. 2014; 55:13-31.
24. Zehnder D, Bland R, Williams MC, McNinch RW, Howie AJ, Stewart PM and Hewison M. Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. The Journal of clinical endocrinology and metabolism. 2001; 86:888-894.
25. Alvarez-Diaz S, Valle N, Garcia JM, Pena C, Freije JM, Quesada V, Astudillo A, Bonilla F, Lopez-Otin C and Munoz A. Cystatin D is a candidate tumor suppressor gene induced by vitamin D in human colon cancer cells. The Journal of clinical investigation. 2009; 119:2343-2358.
26. Balbin M, Hall A, Grubb A, Mason RW, Lopez-Otin C and Abrahamson M. Structural and functional characterization of two allelic variants of human cystatin D sharing a characteristic inhibition spectrum against mammalian cysteine proteinases. The Journal of biological chemistry. 1994; 269:23156-23162.
27. Freije JP, Abrahamson M, Olafsson I, Velasco G, Grubb A and Lopez-Otin C. Structure and expression of the gene encoding cystatin D, a novel human cysteine proteinase inhibitor. The Journal of biological chemistry. 1991; 266:20538-20543.
28. Gocheva V and Joyce JA. Cysteine cathepsins and the cutting edge of cancer invasion. Cell cycle. 2007; 6:60-64.
29. Hollstein M, Sidransky D, Vogelstein B and Harris CC. p53 mutations in human cancers. Science. 1991; 253:49-53.
30. Vogelstein B, Lane D and Levine AJ. Surfing the p53 network. Nature. 2000; 408:307-310.
31. el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW and Vogelstein B. Definition of a consensus binding site for p53. Nature genetics. 1992; 1:45-49.
32. Funk WD, Pak DT, Karas RH, Wright WE and Shay JW. A transcriptionally active DNA-binding site for human p53 protein complexes. Molecular and cellular biology. 1992; 12:2866-2871.
33. Menendez D, Inga A and Resnick MA. The expanding universe of p53 targets. Nature reviews Cancer. 2009; 9:724-737.
34. Maruyama R, Aoki F, Toyota M, Sasaki Y, Akashi H, Mita H, Suzuki H, Akino K, Ohe-Toyota M, Maruyama Y, Tatsumi H, Imai K, Shinomura Y and Tokino T. Comparative genome analysis identifies the vitamin D receptor gene as a direct target of p53-mediated transcriptional activation. Cancer research. 2006; 66:4574-4583.
35. Kommagani R, Payal V and Kadakia MP. Differential regulation of vitamin D receptor (VDR) by the p53 Family: p73-dependent induction of VDR upon DNA damage. The Journal of biological chemistry. 2007; 282:29847-29854.
36. Saramaki A, Banwell CM, Campbell MJ and Carlberg C. Regulation of the human p21(waf1/cip1) gene promoter via multiple binding sites for p53 and the vitamin D3 receptor. Nucleic acids research. 2006; 34:543-554.
37. Chen H, Reed G, Guardia J, Lakhan S, Couture O, Hays E and Chandar N. Vitamin D directly regulates Mdm2 gene expression in osteoblasts. Biochemical and biophysical research communications. 2013; 430:370-374.
38. Stambolsky P, Tabach Y, Fontemaggi G, Weisz L, Maor-Aloni R, Siegfried Z, ShiffI, Kogan I, Shay M, Kalo E, Blandino G, Simon I, Oren M and Rotter V. Modulation of the vitamin D3 response by cancer-associated mutant p53. Cancer cell. 2010; 17:273-285.
39. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW and Vogelstein B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science. 1998; 282:1497-1501.
40. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N and Liu EA. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004; 303:844-848.
41. Joyce JA and Hanahan D. Multiple roles for cysteine cathepsins in cancer. Cell cycle. 2004; 3:1516-1619.
42. Joyce JA, Baruch A, Chehade K, Meyer-Morse N, Giraudo E, Tsai FY, Greenbaum DC, Hager JH, Bogyo M and Hanahan D. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer cell. 2004; 5:443-453.
43. Schagdarsurengin U, Pfeifer GP and Dammann R. Frequent epigenetic inactivation of cystatin M in breast carcinoma. Oncogene. 2007; 26:3089-3094.
44. Zhang J, Shridhar R, Dai Q, Song J, Barlow SC, Yin L, Sloane BF, Miller FR, Meschonat C, Li BD, Abreo F and Keppler D. Cystatin m: a novel candidate tumor suppressor gene for breast cancer. Cancer research. 2004; 64:6957-6964.
45. Giovannucci E. Vitamin D status and cancer incidence and mortality. Advances in experimental medicine and biology. 2008; 624:31-42.
46. Ng K, Meyerhardt JA, Wu K, Feskanich D, Hollis BW, Giovannucci EL and Fuchs CS. Circulating 25-hydroxyvitamin d levels and survival in patients with colorectal cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2008; 26:2984-2991.
47. Garland CF, Garland FC, Gorham ED, Lipkin M, Newmark H, Mohr SB and Holick MF. The role of vitamin D in cancer prevention. American journal of public health. 2006; 96:252-261.
48. Tomasetti C and Vogelstein B. Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science. 2015; 347:78-81.
49. Holick MF and Chen TC. Vitamin D deficiency: a worldwide problem with health consequences. The American journal of clinical nutrition. 2008; 87:1080S-1086S.
50. Anderson MG, Nakane M, Ruan X, Kroeger PE and Wu-Wong JR. Expression of VDR and CYP24A1 mRNA in human tumors. Cancer chemotherapy and pharmacology. 2006; 57:234-240.
51. Cross HS, Bareis P, Hofer H, Bischof MG, Bajna E, Kriwanek S, Bonner E and Peterlik M. 25-Hydroxyvitamin D(3)-1alpha-hydroxylase and vitamin D receptor gene expression in human colonic mucosa is elevated during early cancerogenesis. Steroids. 2001; 66:287-292.
52. Matusiak D, Murillo G, Carroll RE, Mehta RG and Benya RV. Expression of vitamin D receptor and 25-hydroxyvitamin D3-1{alpha}-hydroxylase in normal and malignant human colon. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2005; 14:2370-2376.
53. Sheinin Y, Kaserer K, Wrba F, Wenzl E, Kriwanek S, Peterlik M and Cross HS. In situ mRNA hybridization analysis and immunolocalization of the vitamin D receptor in normal and carcinomatous human colonic mucosa: relation to epidermal growth factor receptor expression. Virchows Archiv: an international journal of pathology. 2000; 437:501-507.
54. Larriba MJ and Munoz A. SNAIL vs vitamin D receptor expression in colon cancer: therapeutics implications. British journal of cancer. 2005; 92:985-989.
55. Fearon ER and Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990; 61:759-767.
56. Selivanova G and Wiman KG. Reactivation of mutant p53: molecular mechanisms and therapeutic potential. Oncogene. 2007; 26:2243-2254.
57. Abe J, Nakano T, Nishii Y, Matsumoto T, Ogata E and Ikeda K. A novel vitamin D3 analog, 22-oxa-1,25-dihydroxyvitamin D3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia. Endocrinology. 1991; 129:832-837.
58. Abe-Hashimoto J, Kikuchi T, Matsumoto T, Nishii Y, Ogata E and Ikeda K. Antitumor effect of 22-oxa-calcitriol, a noncalcemic analogue of calcitriol, in athymic mice implanted with human breast carcinoma and its synergism with tamoxifen. Cancer research. 1993; 53:2534-2537.
59. Cho YL, Christensen C, Saunders DE, Lawrence WD, Deppe G, Malviya VK and Malone JM. Combined effects of 1,25-dihydroxyvitamin D3 and platinum drugs on the growth of MCF-7 cells. Cancer research. 1991; 51:2848-2853.
60. Kota BP, Allen JD and Roufogalis BD. The effect of vitamin D3 and ketoconazole combination on VDRmediated P-gp expression and function in human colon adenocarcinoma cells: implications in drug disposition and resistance. Basic & clinical pharmacology & toxicology. 2011; 109:97-102.
61. Opolski A, Wietrzyk J, Siwinska A, Marcinkowska E, Chrobak A, Radzikowski C and Kutner A. Biological activity in vitro of side-chain modified analogues of calcitriol. Current pharmaceutical design. 2000; 6:755-765.
62. Pelczynska M, Switalska M, Maciejewska M, Jaroszewicz I, Kutner A and Opolski A. Antiproliferative activity of vitamin D compounds in combination with cytostatics. Anticancer research. 2006; 26:2701-2705.
63. Ravid A, Rocker D, Machlenkin A, Rotem C, Hochman A, Kessler-Icekson G, Liberman UA and Koren R. 1,25-Dihydroxyvitamin D3 enhances the susceptibility of breast cancer cells to doxorubicin-induced oxidative damage. Cancer research. 1999; 59:862-867.
64. Siwinska A, Opolski A, Chrobak A, Wietrzyk J, Wojdat E, Kutner A, Szelejewski W and Radzikowski C. Potentiation of the antiproliferative effect in vitro of doxorubicin, cisplatin and genistein by new analogues of vitamin D. Anticancer research. 2001; 21:1925-1929.
65. Kim NH, Kim HS, Li XY, Lee I, Choi HS, Kang SE, Cha SY, Ryu JK, Yoon D, Fearon ER, Rowe RG, Lee S, Maher CA, Weiss SJ and Yook JI. A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial-mesenchymal transition. The Journal of cell biology. 2011; 195:417-433.
66. Siemens H, Jackstadt R, Hunten S, Kaller M, Menssen A, Gotz U and Hermeking H. miR-34 and SNAIL form a double-negative feedback loop to regulate epithelialmesenchymal transitions. Cell cycle. 2011; 10:4256-4271.
67. Chang CJ, Chao CH, Xia W, Yang JY, Xiong Y, Li CW, Yu WH, Rehman SK, Hsu JL, Lee HH, Liu M, Chen CT, Yu D and Hung MC. p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nature cell biology. 2011; 13:317-323.
68. Shi L, Jackstadt R, Siemens H, Li H, Kirchner T and Hermeking H. p53-induced miR-15a/16-1 and AP4 form a double-negative feedback loop to regulate epithelialmesenchymal transition and metastasis in colorectal cancer. Cancer research. 2014; 74:532-542.
69. Palmer HG, Larriba MJ, Garcia JM, Ordonez-Moran P, Pena C, Peiro S, Puig I, Rodriguez R, de la Fuente R, Bernad A, Pollan M, Bonilla F, Gamallo C, de Herreros AG and Munoz A. The transcription factor SNAIL represses vitamin D receptor expression and responsiveness in human colon cancer. Nature medicine. 2004; 10:917-919.
70. Lim SO, Kim H and Jung G. p53 inhibits tumor cell invasion via the degradation of snail protein in hepatocellular carcinoma. FEBS letters. 2010; 584:2231-2236.
71. Jackstadt R, Roh S, Neumann J, Jung P, Hoffmann R, Horst D, Berens C, Bornkamm GW, Kirchner T, Menssen A and Hermeking H. AP4 is a mediator of epithelial-mesenchymal transition and metastasis in colorectal cancer. The Journal of experimental medicine. 2013; 210:1331-1350.
72. Tarasov V, Jung P, Verdoodt B, Lodygin D, Epanchintsev A, Menssen A, Meister G and Hermeking H. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell cycle. 2007; 6:1586-1593.
73. Amati B, Frank SR, Donjerkovic D and Taubert S. Function of the c-Myc oncoprotein in chromatin remodeling and transcription. Biochimica et biophysica acta. 2001; 1471:M135-145.